Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 11/20 | 0.56 |
| ▸ | CLK3 | P49761 | 11/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.56 |
| ▸ | WNT1 | P04628 | 6/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.48 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17569323 | 0.94 | CLK2 (0.57) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569223 | 0.92 | CLK2 (0.58) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569296 | 0.92 | CLK2 (0.55) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569266 | 0.92 | WNT1 (0.49) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17588060 | 0.91 | CLK2 (0.59) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569476 | 0.90 | WNT1 (0.59) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569463 | 0.89 | CLK2 (0.70) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569269 | 0.89 | CLK2 (0.56) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569351 | 0.89 | CLK2 (0.70) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17569252 | 0.88 | CLK2 (0.59) | CLK2CLK3DYRK1AWNT1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206929-B2 | 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-9889140-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889140-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-08-10 | — | — | US | disclosed |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-08-10 | — | — | US | disclosed |
| US-9493487-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493487-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 2369/4885CLK3 2155/4885DYRK1A 949/4885 |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 2369/4885CLK3 2155/4885DYRK1A 949/4885 |
| US-10206929-B2 | 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 2369/4885CLK3 2155/4885DYRK1A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.